OBJECTIVE: To determine the clinical course of noninvasive uterine papillary serous carcinoma and whether it indicates advanced metastatic disease. METHODS: We reviewed the charts of women with noninvasive uterine papillary serous carcinoma who were treated at our institution and abstracted surgical stage, sites of metastases, disease progression, and length of follow-up. RESULTS: There were 595 cases of endometrial adenocarcinoma between January 1990 and February 2000, 69 of which had papillary serous histology. Sixteen were noninvasive tumors. Six were confirmed stage IA by complete surgical staging and ten were associated with metastasis at staging. Two of the six women with stage IA tumors had disease recurrence. CONCLUSIONS: Noninvasive papillary serous carcinoma is often widely metastatic. In our experience, approximately two thirds of patients had metastasis, indicating the need for complete surgical staging. Even in those with disease limited to the endometrium, a significant percentage will have disease recurrence.
OBJECTIVE: To determine the clinical course of noninvasive uterine papillary serous carcinoma and whether it indicates advanced metastatic disease. METHODS: We reviewed the charts of women with noninvasive uterine papillary serous carcinoma who were treated at our institution and abstracted surgical stage, sites of metastases, disease progression, and length of follow-up. RESULTS: There were 595 cases of endometrial adenocarcinoma between January 1990 and February 2000, 69 of which had papillary serous histology. Sixteen were noninvasive tumors. Six were confirmed stage IA by complete surgical staging and ten were associated with metastasis at staging. Two of the six women with stage IA tumors had disease recurrence. CONCLUSIONS: Noninvasive papillary serous carcinoma is often widely metastatic. In our experience, approximately two thirds of patients had metastasis, indicating the need for complete surgical staging. Even in those with disease limited to the endometrium, a significant percentage will have disease recurrence.
Authors: Brooke A Schlappe; Amy L Weaver; Michaela E McGree; Jennifer Ducie; Ane Gerda Zahl Eriksson; Sean C Dowdy; William A Cliby; Gretchen E Glaser; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao Journal: Gynecol Oncol Date: 2019-11-24 Impact factor: 5.482
Authors: Mary C Tolcher; Elizabeth M Swisher; Fabiola Medeiros; Joema F Lima; Jodi L Hilderbrand; Janis L Donovan; Rochelle L Garcia; William A Cliby; Sean C Dowdy Journal: Int J Gynecol Pathol Date: 2015-01 Impact factor: 2.762
Authors: Tilley Jenkins Vogel; Abhay Knickerbocker; Chirag A Shah; Melissa A Schiff; Christina Isacson; Rochelle L Garcia; Barbara A Goff Journal: J Gynecol Oncol Date: 2014-11-06 Impact factor: 4.401